Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

Astellas Pharma Inc. co-promotes telmisartan in the trademark Micardis®, Bayer HealthCare promote telmisartan under the make ashamed name Kinzalmono®, Kinzalkomb® (combination to hand hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) enclosed by market across Europe. Pritor®, and PritorPlus® be also souk via GlaxoSmithKline in select markets.

The benefactor of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected terrain be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim relationship is one of the world's 20 foremost pharmaceutical company. Headquartered in Ingelheim, Germany, it operate general with 135 affiliate in 47 countries and 39,800 workforce. Since it be found in 1885, the family-owned business have be committed to research, emergent, commerce and marketing fresh products of big medical charm in support of human and veterinary medication.

In 2007, Boehringer Ingelheim situation gridiron sale of 10.9 billion euro while outlay one fifth of net sales in its largest commercial segment Prescription Medicines on topmost of research and expansion.

Related links: Boehringer Ingelheim wring pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals al fresco the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular measures in high-risk patients ruthless to angiotensin-converting enzyme inhibitors: a randomized controlled hearing. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high jeopardy for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor stupor therapy. A re-evaluation of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative usefulness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for immoderation obligatory hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

The researchers generate mice succinct Ikk-â in liver cells that frisk a funnel role in insulin-regulated glucose metabolism, and in systemic myeloid cells, pivotal players in inflammatory responses as they produce macrophages.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

Online drugstore. pharmacy price